A prospective phase I/II, one-arm, one-stage multi-center, open label study of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan in patients with relapsed or refractory or progressive multiple myeloma: Third-line therapy.

Trial Profile

A prospective phase I/II, one-arm, one-stage multi-center, open label study of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan in patients with relapsed or refractory or progressive multiple myeloma: Third-line therapy.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone; Pioglitazone; Treosulfan
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 May 2012 Planned end date changed from 1 Feb 2012 to 1 Oct 2016 as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Official Title amended as reported by European Clinical Trials Database record.
    • 17 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top